Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
Mona Darwish(Bridge Pharma (United States)), Lynn R. Webster(Adherent Technologies (United States)), William Tracewell(Teva Pharmaceuticals (United States)), Philmore Robertson(Teva Pharmaceuticals (United States)), Yuju Ma(Ocean University of China), Mary Lou Bond(Teva Pharmaceuticals (United States))
Cited by 12
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309
A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain
|Journal of Pain and Symptom Management|2006|304